STOCK TITAN

KALA BIO must meet $1 bid test by Nov. 30 for listing

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

KALA BIO, Inc. received a Nasdaq Hearings Panel decision allowing continued listing on The Nasdaq Capital Market, subject to conditions. The decision followed a staff determination that KALA’s closing bid price was below $1.00 per share for 30 consecutive business days, from July 16 through August 26, 2026. KALA must evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026, then maintain a closing bid price of at least $1.00 for each trading day after November 30 until February 23, 2027.

If KALA maintains compliance until February 23, 2027, the Panel intends to impose a discretionary monitor for the next year. The Panel reserved the right to reconsider its decision if, in its opinion, an event, condition or circumstance makes continued listing inadvisable or unwarranted. KALA said there can be no assurance it will meet the conditions or maintain compliance with continued-listing requirements.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.Nasdaq listing remains conditional on meeting the $1.00 bid-price tests.

Filing Explained

The decision also covers a breach of another Nasdaq listing rule before February 23, 2027: KALA has seven days to tell the Panel its cure plan, after which the Panel decides whether to allow an exception to cure the breach or delist the company.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Minimum closing bid price $1.00 per share Required for ten consecutive business days by November 30, 2026, and for each trading day after that until February 23, 2027.
Period below minimum bid price 30 consecutive business days Nasdaq staff determined the closing bid was below $1.00 per share from July 16 through August 26, 2026.
Initial price-compliance period 10 consecutive business days The closing bid must be at least $1.00 per share by November 30, 2026.
Response period for another listing deficiency 7 days Applies if KALA becomes noncompliant with another Nasdaq listing rule before February 23, 2027.
Discretionary monitor period Next year The Panel intends to impose a monitor if KALA maintains compliance until February 23, 2027.
minimum bid price requirement regulatory
"not in compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"set forth in Nasdaq Listing Rule 5550(a)(2)"
discretionary monitor regulatory
"impose a discretionary monitor for the next year"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KALA need to do to keep its Nasdaq listing?

The Panel requires KALA to evidence a closing bid of at least $1.00 per share for ten consecutive business days by November 30, 2026, then maintain a closing bid of at least $1.00 for each trading day after November 30 until February 23, 2027. If another Nasdaq listing-rule deficiency occurs before February 23, KALA has seven days to advise the Panel of its plan to cure it; the Panel will decide whether to grant an exception or delist KALA.

Will KALA be monitored after meeting Nasdaq’s conditions?

If KALA maintains compliance until February 23, 2027, the Panel intends to impose a discretionary monitor for the next year. The Panel reserved the right to reconsider its decision based on any event, condition or circumstance that, in the Panel’s opinion, would make continued listing inadvisable or unwarranted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001479419 0001479419 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

 

 

KALA BIO, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38150   27-0604595
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1167 Massachusetts Avenue

Arlington, MA

  02476
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 996-5252

 

Not applicable

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   KALA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 8.01 Other Items.

 

On August 27, 2026, KALA BIO, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), has been below $1.00 per share for the previous 30 consecutive business days (from July 16, 2026 through August 26, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2).

 

On October 6, 2026, the Company met with the Nasdaq Hearings Panel (the “Panel”). On November 13, 2026, the Panel granted the Company’s request to continue its listing on Nasdaq subject to the following conditions: (i) the Company shall evidence a closing bid price of at least $1.00 per share for ten consecutive business days by November 30, 2026; (ii) the Company must maintain a closing bid price of at least $1.00 for each trading day after November 30, 2026 until February 23, 2027; and (iii) if the Company becomes non-compliant with any other Nasdaq listing rule prior to February 23, 2027, the Company will be allowed seven days to advise the Panel on the Company’s plan to cure the listing deficiency and the Panel shall determine whether to grant the Company an exception to cure the deficiency or delist the Company. If the Company maintains compliance until February 23, 2027, the Panel intends to impose a discretionary monitor for the next year. The Panel has reserved the right to reconsider its decision based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Common Stock on Nasdaq inadvisable or unwarranted.

 

There can be no assurance that the Company will be able meet the Panel’s conditions or maintain compliance with the requirements for continued listing on The Nasdaq Capital Market.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s ability to meet the Panel’s condition and its future maintenance of compliance with the Nasdaq continued listing requirements. Forward-looking statements are subject to a number of risks and uncertainties, including that the Company may not be able to satisfy the Panel’s conditions and other risks and uncertainties set forth from time to time in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  KALA BIO, INC.
     
Date: November 16, 2026 By: /s/ Avi Minkowitz
    Avi Minkowitz
    Chief Executive Officer

 

2

Filing Exhibits & Attachments

3 documents

Keep reading